Kim Monkhorst - Concepedia

Author

Kim Monkhorst

The Netherlands Cancer Institute ORCID

Also Known As

Anne Marie Quinn, Gerrit A. Meijer, K Monkhorst, K. Monkhorst, Kim Monkhorst, Paul Baas

381

Publications

7.2K

Citations

H-Index

100

Concepts

All Affiliations

The Netherlands Cancer Institute Oncode Institute Erasmus MC University Medical Center Utrecht Radboud University Nijmegen

About

Kim Monkhorst is an author at The Netherlands Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	34	3.6K
2	Health Sciences	7	8	433
3	Public Health	2	2	60
4	Social Sciences	1	1	164
5	Biomedical Engineering	1	1	20

Kim Monkhorst

Publications

6.6K

Citations

H-Index

Page 1

	Year	Citations
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids Krijn K. Dijkstra, Chiara M. Cattaneo, Fleur Weeber, Cell Tumor-reactive T CellsCell TherapyCancer ImmunosurveillancePeripheral Blood LymphocytesT-regulatory Cell	2018	1K
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer Willemijn S.M.E. Theelen, Heike Peulen, Ferry Lalezari, JAMA Oncology	2019	935
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer Paula Voabil, Marjolein de Bruijn, Lisanne M. Roelofsen, Nature Medicine Pd-1 BlockadeMedicineTumor ImmunityImmune Checkpoint InhibitorTumor Targeting	2021	336
SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin Giustina Ferone, Ji‐Ying Song, Rajith Bhaskaran, Cancer Cell OncologyHuman LsccPten Loss ResultsOncogenic AgentDetermining Oncogenic Switch	2016	246
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma Josine M.M.F. Quispel-Janssen, Vincent van der Noort, Jeltje F. de Vries, Journal of Thoracic Oncology	2018	244
Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine Krijn K. Dijkstra, Kim Monkhorst, Luuk J. Schipper, Cell Reports	2020	244
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial Maria Disselhorst, Josine M.M.F. Quispel-Janssen, Ferry Lalezari, The Lancet Respiratory Medicine OncologyPleural DiseaseCancer TreatmentMedicineRadiation Oncology	2019	243
RNF12 Is an X-Encoded Dose-Dependent Activator of X Chromosome Inactivation Iris H. Jonkers, Tahsin Stefan Barakat, Eskeatnaf Mulugeta, Cell ChromatinTranscriptional RegulationGenome InstabilityChromosome BiologyX Chromosome Inactivation	2009	229
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer Valsamo Anagnostou, Noushin Niknafs, Kristen A. Marrone, Nature Cancer Cancer ImmunosurveillanceNon-small-cell Lung CancerMedicineImmunologyCancer Genomics	2020	204
X Inactivation Counting and Choice Is a Stochastic Process: Evidence for Involvement of an X-Linked Activator Kim Monkhorst, Iris H. Jonkers, Eveline Rentmeester, Cell Cognitive ScienceBehavioral Decision MakingX Inactivation CountingSocial SciencesProbability Theory	2008	164

Page 1